Featured Press Releases

West introduces Daikyo PLASCAP® RUV closures in a new nested format at Pharmapack

West introduces Daikyo PLASCAP® RUV closures in a new nested format at Pharmapack

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

  • 07 Aug 2024

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of...

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

The American Kidney Fund

The American Kidney Fund's Rare Kidney Disease Advocacy Day on Capitol Hill aims to gather support for legislation to boost awareness and treatment of rare kidney diseases.

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

SHARx Focuses on Rx Continuity for Employers and Patients as Customs Requirements Change

SHARx Focuses on Rx Continuity for Employers and Patients as Customs Requirements Change

  • SHARx
  • 28 Sep 2026
Zifo Unveils Vision for an AI-Driven Scientific Semantic Layer in Biopharma

Zifo Unveils Vision for an AI-Driven Scientific Semantic Layer in Biopharma

  • Zifo
  • 28 Sep 2026
ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

ImmunoScape Appoints Peter Olagunju as Chief Executive Officer

  • ImmunoScape Pte. Ltd.
  • 23 Sep 2026
LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

  • LEVEL
  • 22 Sep 2026
FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

  • Merck & Co., Inc.
  • 22 Sep 2026
Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

Padagis Expands Workplace Naloxone Access by Providing Free Nasal Sprays to Qualifying Businesses

  • Padagis
  • 21 Sep 2026

Most Popular
September   2026
M T W T F S S
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.